Growing Prevalence of Cancer
The growing prevalence of cancer patients has a direct impact on increased demand for the histology and cytology market. According to the 2012 report of the World Health Organization (WHO), there were 14 million new cases of cancers, which were expected to rise by about 70% over the next two decades. In the US, as per the National Cancer Institute report of 2018, an estimated 1.73 million new cases of cancer diagnosed in the United States and nearly 0.61 million people died from the disease. The histological methods help in increasing the sensitivity, specificity, and accuracy of diagnostic methods. Similarly, the combined methods help in better diagnosis of diseases such breast cancer and lung cancer. Thus, the prevalence of cancer plays a vital role in increasing the demand of histology and cytology market.
Other driving factors include increasing standardization of pathological laboratories, technological advancement in the diagnostics and molecular techniques, and favorable reimbursement for cancer screening and laboratory tests.
Saftey Issues and Diagnostic Accuracy Issues with Histopathological and Cytopathological Tests
The safety issues and diagnostic accuracy is one of the primary factor hindering this market. The safety issues are mainly related to potentially hazardous chemicals, biohazardous materials, accidents linked to the equipment and instrumentation. According to the 2013 publication in the Journal of Oral and Maxillofacial Pathology, even though the accuracy of frozen artifacts ranges between 89% — 98%, the frozen nature produces inferior slides for microscopic examination and sampling errors, which results from the heterogeneity of a tumor. Thus, this factor is one of the key aspects hindering the usage of histology and cytology in the research labs and diagnostic centers.
Another factor hindering the growth of this market is the lack of awareness among public for diagnostic tests.
Asia-Pacific to Register the Fastest Growth
Asia-Pacific is expected to dominate with the fastest growth rate in the forecast period. The healthy CAGR is expected due to the surge in the scientific researches in the South Asian countries. Novel opportunities are further enhanced by the rising number of long-term collaborations of multinational companies with domestic manufacturers and research laboratories in this region.
This is followed by the wide diversified patient pool of cancer and genetic disorders with rising role of personalized medicine in the treatment of genetic and other disorders. North America is expected to dominate the market with a large number of clinical research laboratories and academic institutes with better regulatory framework in the countries of this region.
Key Developments in the Market
- February 2018 – BD received premarket approval from the US FDA for the BD Onclarity HPV assay, which can detect 14 types of high-risk human papillomavirus (HPV) from the specimens collected for cervical cancer screening.
Reasons to Purchase the Repor:t
- Current and future of the global histology and cytology market outlook in the developed and emerging markets.
- Analysis of various perspectives of the market with the help of Porter’s Five Forces Analysis.
- The segment that is expected to dominate the market.
- Regions that are expected to witness the fastest growth during the forecast period.
- Identify the latest developments, market shares, and strategies employed by the major market players.
- 3-month analyst support, along with the Market Estimate sheet (in Excel).
This report can be customized to meet your requirements. Please contact us for more information.
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter's Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Products and Services
5.2.5 Competitive Rivalry
6. Market Dynamics
6.1.1 Rising Prevalence of Cancer
6.1.2 Increasing Standardization of Pathological Laboratories
6.1.3 Technological Advancement in the Diagnostic and Molecular Techniques
6.1.4 Favorable Reimbursements for Cancer Screening and Laboratory Tests
6.2.1 Safety Issues and Diagnostic Accuracy Issues with Histopathological and Cytopathological Tests
6.2.2 Lack of Awareness among Public for Diagnostic Tests
6.4 Key Challenges
7. Market Segmentation
7.1 By Type of Examination
126.96.36.199 Breast Cancer
188.8.131.52 Cervical Cancer
7.2 By Test Type
7.2.1 Microscopy-based Tests
184.108.40.206 Cytochemistry and Histochemistry
220.127.116.11 Immunohistochemistry and Immunofluoroscence
7.2.2 Molecular Genetics Tests
18.104.22.168 Cytogenic Tests
22.214.171.124.2 Fluorescent in Situ Hybridization (FISH)
126.96.36.199 Polymerase Chain Reaction
7.2.3 Flow Cytometry
7.3 By End User
7.3.2 Biopharmaceutical Companies
7.4 By Geography
7.4.1 North America
188.8.131.52 United States
184.108.40.206 Rest of North America
220.127.116.11 United Kingdom
18.104.22.168 Rest of Europe
22.214.171.124 South Korea
126.96.36.199 Rest of Asia-Pacific
7.4.4 Middle East & Africa
188.8.131.52 South Africa
184.108.40.206 Rest of Middle East & Africa
7.4.5 South America
220.127.116.11 Rest of South America
8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.2 Becton Dickinson and Company
9.4 F. Hoffmann-La Roche Ltd
9.5 Hologic, Inc.
9.6 Merck KGaA
9.7 PerkinElmer, Inc.
9.8 Sysmex Corporation
9.9 Thermo Fisher Scientific, Inc.
9.10 Trivitron Healthcare
*List not Exhaustive
10. Future of the Market